Nektar Therapeutics Weighted Average Number of Shares Outstanding, Basic and Diluted
Nektar Therapeutics (NKTR) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 181.37 million shares for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-07.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2021-05-07
- Nektar Therapeutics weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-03-31 was 181.37M shares, a 2.36% increase year-over-year.
- Nektar Therapeutics weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-09-30 was 179.09M shares, a 2.10% increase year-over-year.
- Nektar Therapeutics weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-06-30 was 178.33M shares, a 2.16% increase year-over-year.
- Nektar Therapeutics weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-03-31 was 177.19M shares, a 1.91% increase year-over-year.
- Nektar Therapeutics weighted average number of shares outstanding, basic and diluted for fiscal 2017 was 155.95M shares, a 11.72% increase from fiscal 2016.
- Nektar Therapeutics weighted average number of shares outstanding, basic and diluted for fiscal 2016 was 139.60M shares, a 5.39% increase from fiscal 2015.
- Nektar Therapeutics weighted average number of shares outstanding, basic and diluted for fiscal 2015 was 132.46M shares, a 4.40% increase from fiscal 2014.
- Nektar Therapeutics weighted average number of shares outstanding, basic and diluted for fiscal 2014 was 126.87M shares, a 9.63% increase from fiscal 2013.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2021-03-31 | 181.37M shares 10-Q · filed 2021-05-07 | |||
| 2020-09-30 | 179.09M shares 10-Q · filed 2020-11-06 | 178.71M shares derived: average of 2 quarters · filed 2020-11-06 | 178.20M shares 10-Q · filed 2020-11-06 | |
| 2020-06-30 | 178.33M shares 10-Q · filed 2020-08-07 | 177.75M shares 10-Q · filed 2020-08-07 | ||
| 2020-03-31 | 177.19M shares 10-Q · filed 2021-05-07 | |||
| 2019-09-30 | 175.40M shares 10-Q · filed 2020-11-06 | 174.98M shares derived: average of 2 quarters · filed 2020-11-06 | 174.61M shares 10-Q · filed 2020-11-06 | |
| 2019-06-30 | 174.55M shares 10-Q · filed 2020-08-07 | 174.21M shares 10-Q · filed 2020-08-07 | ||
| 2019-03-31 | 173.86M shares 10-Q · filed 2020-05-08 | |||
| 2018-03-31 | 160.88M shares 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | 155.95M shares 10-K · filed 2018-03-01 | |||
| 2017-06-30 | 155.35M shares 10-Q · filed 2017-08-09 | 154.51M shares 10-Q · filed 2017-08-09 | 152.72M shares derived: average of 3 quarters · filed 2018-05-10 | 148.81M shares derived: average of 4 quarters · filed 2018-05-10 |
| 2017-03-31 | 153.67M shares 10-Q · filed 2018-05-10 | 151.40M shares derived: average of 2 quarters · filed 2018-05-10 | 146.63M shares derived: average of 3 quarters · filed 2018-05-10 | 144.06M shares derived: average of 4 quarters · filed 2018-05-10 |
| 2016-12-31 | 149.14M shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | 143.12M shares derived: average of 2 quarters · filed 2018-03-01 | 140.86M shares derived: average of 3 quarters · filed 2018-03-01 | 139.60M shares 10-K · filed 2018-03-01 |
| 2016-09-30 | 137.09M shares 10-Q · filed 2016-11-04 | 136.72M shares derived: average of 2 quarters · filed 2017-08-09 | 136.41M shares 10-Q · filed 2016-11-04 | 135.86M shares derived: average of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | 136.35M shares 10-Q · filed 2017-08-09 | 136.07M shares 10-Q · filed 2017-08-09 | 135.44M shares derived: average of 3 quarters · filed 2018-03-01 | 134.74M shares derived: average of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | 135.79M shares 10-Q · filed 2017-05-10 | 134.99M shares derived: average of 2 quarters · filed 2018-03-01 | 134.20M shares derived: average of 3 quarters · filed 2018-03-01 | 133.56M shares derived: average of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | 134.19M shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | 133.41M shares derived: average of 2 quarters · filed 2018-03-01 | 132.82M shares derived: average of 3 quarters · filed 2018-03-01 | 132.46M shares 10-K · filed 2018-03-01 |
| 2015-09-30 | 132.63M shares 10-Q · filed 2016-11-04 | 132.14M shares derived: average of 2 quarters · filed 2016-11-04 | 131.88M shares 10-Q · filed 2016-11-04 | |
| 2015-06-30 | 131.64M shares 10-Q · filed 2016-08-04 | 131.50M shares 10-Q · filed 2016-08-04 | ||
| 2014-12-31 | 126.87M shares 10-K · filed 2017-03-01 | |||
| 2014-06-30 | 127.04M shares 10-Q · filed 2015-08-06 | 125.30M shares 10-Q · filed 2015-08-06 | 122.28M shares derived: average of 3 quarters · filed 2016-02-29 | 120.66M shares derived: average of 4 quarters · filed 2016-02-29 |
| 2014-03-31 | 123.54M shares 10-Q · filed 2014-05-08 | 119.90M shares derived: average of 2 quarters · filed 2016-02-29 | 118.54M shares derived: average of 3 quarters · filed 2016-02-29 | 117.79M shares derived: average of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | 116.26M shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | 116.03M shares derived: average of 2 quarters · filed 2016-02-29 | 115.87M shares derived: average of 3 quarters · filed 2016-02-29 | 115.73M shares 10-K · filed 2016-02-29 |
| 2013-09-30 | 115.81M shares 10-Q · filed 2013-11-07 | 115.68M shares derived: average of 2 quarters · filed 2014-08-01 | 115.56M shares 10-Q · filed 2013-11-07 | 115.46M shares derived: average of 4 quarters · filed 2015-02-26 |
| 2013-06-30 | 115.54M shares 10-Q · filed 2014-08-01 | 115.43M shares 10-Q · filed 2014-08-01 | 115.35M shares derived: average of 3 quarters · filed 2015-02-26 | 115.24M shares derived: average of 4 quarters · filed 2015-02-26 |
| 2013-03-31 | 115.31M shares 10-Q · filed 2014-05-08 | 115.25M shares derived: average of 2 quarters · filed 2015-02-26 | 115.14M shares derived: average of 3 quarters · filed 2015-02-26 | 115.01M shares derived: average of 4 quarters · filed 2015-02-26 |
| 2012-12-31 | 115.18M shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | 115.05M shares derived: average of 2 quarters · filed 2015-02-26 | 114.92M shares derived: average of 3 quarters · filed 2015-02-26 | 114.82M shares 10-K · filed 2015-02-26 |
| 2012-09-30 | 114.92M shares 10-Q · filed 2013-11-07 | 114.78M shares derived: average of 2 quarters · filed 2013-11-07 | 114.70M shares 10-Q · filed 2013-11-07 | |
| 2012-06-30 | 114.65M shares 10-Q · filed 2013-08-09 | 114.59M shares 10-Q · filed 2013-08-09 | ||
| 2011-12-31 | 112.94M shares 10-K · filed 2014-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |